Qualitative detection of NTRK3 and NTRK1 break apart
A new ZytoDot ® 2C probe for detecting NTRK3 rearrangements
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
NTRK1 and NTRK3 rearrangements have been detected in numerous tumor entities. They occur rarely (< 1%) in common entities, but with a high frequency in some rare tumors, e.g., secretory breast carcinoma or infantile fibrosarcoma, making targeted testing by means of in situ hybridization useful here. The fusion genes with different partners are causally involved in tumorigenesis, and the activity of their protein products is inhibited specifically and very effectively by tyrosine kinase inhibitors, such as Larotrectinib and Entrectinib.
Chromogenic in situ hybridization allows stained specimens to be analyzed directly under the light microscope of genomic rearrangements to be assessed in the morphological context. Zytomed Systems provides a kit with all the reagents required to process the specimens, and its components can be reordered individually.
Products
| Product | Manufacturer | Clone | Amount | Status | Order no. | Info | |
|---|---|---|---|---|---|---|---|
| ZytoDot® 2C CISH Implementation Kit | - | 1 Kit (10 Tests) | CE/IVD | C-3044-10 | |||
| ZytoDot® 2C CISH Implementation Kit | - | 1 Kit (40 Tests) | CE/IVD | C-3044-40 | |||
| ZytoDot® 2C SPEC NTRK1 Break Apart Probe | - | 100 µl (10 Tests) | CE/IVD | C-3078-100 | |||
| ZytoDot® 2C SPEC NTRK3 Break Apart Probe | - | 100 µl (10 Tests) | CE/IVD | C-3079-100 |
Further topics
Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
The new GATA antibody
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)
